Research programme: antibody therapeutics - Schrdinger/Twist Bioscience
Latest Information Update: 28 Feb 2024
At a glance
- Originator Schrodinger; Twist Bioscience
- Developer Twist Bioscience
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for research development in Unspecified in USA (Parenteral)
- 30 Jan 2020 Research programme: antibody therapeutics - Schrdinger/Twist Bioscience is available for licensing as of 16 Jan 2020. https://www.twistbioscience.com/
- 16 Jan 2020 Twist Bioscience and Schrdinger collaborate to develop drugs targeting G-protein coupled receptor